Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

Glenview Capital Management, LLC accrued its presumption successful Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 868,457 shares successful the 3rd quarter, adding astir $71.98 cardinal successful value, according to a November 14, 2025, SEC filing.

Glenview Capital Management reported a nett summation of 868,457 shares successful Teva Pharmaceutical Industries Limited during the 3rd quarter, according to a filing with the U.S. Securities and Exchange Commission dated November 14, 2025. The position’s worth roseate to $337.19 cardinal arsenic of September 30, 2025, reflecting terms appreciation and further stock accumulation.

The money accrued its Teva stake, which present accounts for 7.51% of 13F AUM and ranks arsenic its 4th-largest holding.

Top holdings aft the filing:

• NYSE:CVS: $617.96 cardinal (13.8% of AUM)

• NYSE:THC: $471.80 cardinal (10.5% of AUM)

• NYSE:GPN: $427.19 cardinal (9.5% of AUM)

• NYSE:TEVA: $337.19 cardinal (7.5% of AUM)

• NASDAQ:GTM: $201.89 cardinal (4.5% of AUM)

As of December 05, 2025, shares were priced astatine $28.46, up 63.5% implicit the past year, outperforming the S&P 500 by 49.6 percent points.

• Teva Pharmaceutical Industries Limited offers a wide portfolio of generic medicines, specialty pharmaceuticals, and biopharmaceutical products, with cardinal offerings successful cardinal tense system, respiratory, and oncology therapies.

• The institution generates gross chiefly done the development, manufacturing, and planetary organisation of medicine drugs and progressive pharmaceutical ingredients, leveraging some branded and generic merchandise lines.

• Main customers see healthcare providers, hospitals, pharmacies, and wholesalers crossed North America, Europe, and planetary markets.

Teva Pharmaceutical Industries Limited is simply a starring planetary pharmaceutical institution with a important beingness successful the generic and specialty cause markets. The company’s strategy centers connected delivering accessible medicines and leveraging its standard to code a wide scope of therapeutic areas. Its diversified merchandise basal and established organisation web supply a competitory borderline successful serving healthcare systems worldwide.